Study of Fatigue in SMA Patients on Nusinersen
Part of Brain & nervous system clinical trials.
This study looks at how tired you feel during physical activities while being treated with nusinersen (Spinraza) for spinal muscular atrophy (SMA). The goal is to understand how well the treatment helps with daily energy levels.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with SMA type 5q (a specific genetic form of spinal muscular atrophy)
- You are currently taking nusinersen (Spinraza) and have been on a stable dose for at least 6 months
- You have not had an injury or surgery in the past 3 months that would make it hard to do physical tests
- You are not taking part in any other clinical trial, extension study, or registry for a new or recently approved drug
- You are not using any other treatments for SMA, such as muscle-targeting drugs or medications that affect nerve signals
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study is looking for children and teens with spinal muscular atrophy (SMA) who are already on a treatment like Spinraza, Evrysdi, or Zolgensma. The goal is to understand different forms of SMA and how the treatment affects them over time.
This study looks at how muscles work in children and young adults with spinal muscular atrophy (SMA) who are taking or starting SMN-directed therapies (like Evrysdi, Spinraza, or Zolgensma). It aims to understand the body's response to these treatments, which could help improve future care.
This study follows people with spinal muscular atrophy (SMA) who have a particular genetic change in the SMN1 gene. It compares long-term outcomes for those who do and do not receive disease-modifying treatments, to better understand what helps over time.
This trial tests a medicine called salanersen (BIIB115) to see how well it improves movement and how safe it is in people with spinal muscular atrophy (SMA). It includes those who have never taken an SMA drug or are currently on risdiplam and willing to switch.
This is a long-term observation study that follows people affected by spinal muscular atrophy (SMA), people who carry the SMA gene but have no symptoms, and families of people with SMA. It helps researchers better understand SMA and related genetic status, which can support future treatment planning.
This study tests a new device called the ThecaFlex DRx System, which is a small port and catheter placed under the skin to deliver Spinraza directly into spinal fluid—instead of needing repeated spinal taps. The device aims to make receiving medication easier and safer for people with SMA.
Hear when a new Spinal Muscular Atrophy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.